ADH-503
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 408039

CAS#: Unknown

Description: ADH-503 is a potent agonist of the integrin CD11b to mitigate myeloid cell immunosuppression. The partial activation of CD11b by ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhanced dendritic cell responses. These actions, in turn, improve antitumor T cell immunity and render checkpoint inhibitors effective in previously unresponsive PDAC models.


Price and Availability

Size
Price

50mg
USD 450
500mg
USD 2250
Size
Price

100mg
USD 850
1g
USD 3450
Size
Price

200mg
USD 1350
2g
USD 5650

ADH-503, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 408039
Name: ADH-503
CAS#: Unknown
Chemical Formula: C28H32N2O4S2
Exact Mass:
Molecular Weight: 524.694
Elemental Analysis: C, 64.10; H, 6.15; N, 5.34; O, 12.20; S, 12.22


Synonym: ADH-503; ADH 503; ADH503;

IUPAC/Chemical Name: 2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-methyl-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate

InChi Key: HIJWAHUTJVGURK-GNWMQEPYSA-M

InChi Code: InChI=1S/C23H19NO3S2.C5H14NO/c1-15-21(29-23(28)24(15)14-16-5-3-2-4-6-16)13-19-11-12-20(27-19)17-7-9-18(10-8-17)22(25)26;1-6(2,3)4-5-7/h2-13,15H,14H2,1H3,(H,25,26);7H,4-5H2,1-3H3/q;+1/p-1/b21-13-;

SMILES Code: C(=O)([O-])C1C=CC(C2=CC=C(/C=C3\SC(=S)N(CC4=CC=CC=C4)C\3C)O2)=CC=1.[N+](CCO)(C)(C)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


Additional Information

Although checkpoint immunotherapies have revolutionized the treatment of cancer, not all tumor types have seen substantial benefit. Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in which very limited responses to immunotherapy have been observed. Extensive immunosuppressive myeloid cell infiltration in PDAC tissues has been postulated as a major mechanism of resistance to immunotherapy. Strategies concomitantly targeting monocyte or granulocyte trafficking or macrophage survival, in combination with checkpoint immunotherapies, have shown promise in preclinical studies, and these studies have transitioned into ongoing clinical trials for the treatment of pancreatic and other cancer types.